Kyowa Hakko Kogyo Co., Ltd.

Kyowa Hakko Kogyo Kabushiki Kaisha

Kitasato Kenkyusho

Masaji Kasai

Tadashi Ashizawa

Makoto Morimoto

Kunikatsu Shirahata

Motomichi Kono

Hiromitsu Saito

Yutaka Kanda

Katsushige Gomi

Hitoshi Arai

Yutaka Saito

Hiroshi Sano

Yukiteru Mimura

Shinji Tomioka

Takehiro Ogasa

Akira Sato

Chikara Murakata

Hiroshi Kase

Isao Kawamoto

Eiji Kobayashi

Tatsuya Tamaoki

Kazuyuki Mineura

Itaru Takahashi

Shoichi Mizutaki

Kazumi Amatsu

Yoshiyuki Yamada

Satoshi Omura

Ryo Okachi

Fusao Tomita

Haruo Tanaka

Takao Iida

Yoichi Uosaki

Shinzo Ishii

Kiyoshi Nakayama

Yasushi Shida

Yutaka Osawa

Uichiro Kimura

Masahiko Kinugawa

Yasuyuki Ono

Hiroyuki Shinmura

Yasunori Nakaguchi

Kunimi Inoue

Hiroyuki Ishida

Tsutomu Akama

Mitsuru Takahashi

Koji Yamada

Shiro Akinaga

Akira Karasawa

Yoshiharu Yokoo

Katsuichi Shuto

Masami Okabe

Shigeto Kitamura

Tetsuo Oka

Toru Yasuzawa

Toshikazu Kamiya

Tomoya Takahashi

Keiichi Takahashi

Shinkichi Honda

Kimihisa Ueno

Shun-ichi Ikeda

Soichiro Sato

Yoshiaki Masuda

Noriaki Hirayama

Shigeo Katsumata

Yoshikazu Mori

Tatsuhiro Ogawa

Hiroshi Nishikawa

Takashi Mimura

Chikahiro Urakawa

Kinichi Nakano

Nobuo Nakamura

Shuji Okubo

Hiromasa Kato

Yoichiro Arai

Junji Kanazawa

Michio Ichimura

Iwao Chujo

Sachiko Kato

Shun-Ichi Ikeda

Kimihito Sasaki

Takahiro Imai

Etsuko Nukui

Eiichiro Imai

Haruko Tsuchiya

Masanori Fukui

Toshiro Koguchi

Takashi Deguchi

Masayuki Yamato

Kenichi Muroi

Kenji Torii

Provided is a process for efficiently producing N-glycyltyrosine of high purity represented by the following formula:

Process for producing N-glycyltyrosine and its crystal structure

The present invention relates to propenone derivatives represented by the following formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, or YR.sup.5 (wherein Y represents S or O; and R.sup.5 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a substituted or unsubstituted cyclic ether residue); R.sup.2 and R.sup.3 independently represent hydrogen, lower alkyl, or substituted or unsubstituted aralkyl, or alternatively R.sup.2 and R.sup.3 are combined to form substituted or unsubstituted methylene or ethylene; R.sup.4 represents hydrogen, hydroxy, lower alkyl, substituted or unsubstituted aralkyl, lower alkoxy, substituted or unsubstituted aralkyloxy, or halogen; and X represents substituted or unsubstituted indolyl; or pharmaceutically acceptable salts thereof.

Propenone derivatives

N-chloroacetylglutamine is produced by reacting chloroacetyl chloride with an alkaline aqueous solution of glutamine the presence of a water-immiscible organic solvent, separating an aqueous layer by liquid-liquid separation, and crystallizing N-chloroacetyl-glutamine from the aqueous layer under acidic conditions. N-Chloroacetyl-glutamine useful as an intermediate for producing glycyl-L-glutamine which has higher stability than L-glutamine and is used as a component of an infusion solution can be obtained with high efficiency at low cost.

Process for producing glutamine derivative

The present invention relates to glutathione monoester sulfonate represented by formula (I): ##STR1## (wherein R.sup.1 represent lower alkyl, and R.sup.2 represents lower alkyl, or substituted or unsubstituted aryl) which readily crystallizes and has high stability, and a simple process for producing the same. According to the process, the product having high purity can be obtained in high yields.

Glutathione monoester sulfonate

Process for producing indolocarbazole derivatives

Disclosed is a process for producing alanylglutamine, which comprises reacting an N-(2-substituted)-propionylglutamine compound represented by the formula (I): ##STR1## where X represents halogen, alkylsulfonyloxy, or substituted or unsubstituted arylsulfonyloxy, with ammonia at a temperature of 60.degree. C. or below. in accordance with the present invention, highly purified alanylglutamine can be produced in a high yield, without racemization.

Process for producing alanylglutamine

5-Aminoflavone derivatives represented by the formula (I): ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are the same or different and represent hydrogen, substituted or unsubstituted lower alkyl, lower alkenyl, halogen-substituted or unsubstituted lower alkanoyl or lower alkoxycarbonyl, X.sup.1, X.sup.2, Y.sup.1 and Y.sup.2 are the same or different and represent hydrogen, halogen or lower alkyl, at least one of X.sup.1 and X.sup.2 represents halogen or lower alkyl, X.sup.3 represents hydrogen, substituted or unsubstituted lower alkyl, lower alkenyl, lower alkynyl, halogen, hydroxy, substituted or unsubstituted lower alkoxy, NR.sup.5 R.sup.6 (wherein R.sup.5 and R.sup.6 are the same or different and represent hydrogen, or substituted or unsubstituted lower alkyl, or R.sup.5 and R.sup.6 are taken together to form a heterocyclic group containing the nitrogen atom in the ring), lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, carboxy, lower alkoxycarbonyl, lower alkanoyl, adizo, cyano, substituted or unsubstituted carbamoyl or lower alkylthiothiocarbonyl: or pharmaceutically acceptable salts thereof.

5-aminoflavone derivatives

N-acylglutamine derivatives and cosmetic compositions

Disclosed is a process for producing alanylglutamine, which comprises reacting an N-(2-substituted)-propionylglutamine compound represented by the formula (I): ##STR1## where X represents halogen, alkylsulfonyloxy, or substituted or unsubstituted arylsulfonyloxy, with ammonia at a temperature of 60.degree. C. or below. In accordance with the present invention, highly purified alanylglutamine can be produced in a high yield, without racemization.

Process for producing alanylgutamine

An indole derivative represented by formula (I): ##STR1## wherein R.sup.1 is a lower alkoxymethyl group or a formyl group, R.sup.2 is a lower alkyl group, R.sup.3 is a hydrogen atom or a lower alkyl group and R.sup.4 is a hydrogen atom or a lower alkyl group, which is useful as an intermediate for the synthesis of a compound, 5-aziridino-3-hydroxymethyl-l-methyl-2- (1H-indole-4,7-dione)prop-.beta.-ene-.alpha.-ol, which has antitumor activity.

Indole 3-carboxylic acid derivatives

Novel mitomycin derivatives represented by the formula (I) are obtained by introducing a substituent at the 6-position. The mitomycin derivatives of the present invention have an antitumor activity.

6-ethyl mitomycin derivatives

Mitomycin derivatives

Disclosed is pyrazoloacridone derivatives represented by formula (I): ##STR1## wherein: each of R.sup.1a, R.sup.1b, R.sup.1c and R.sup.1d independently represents hydrogen, lower alkyl, --(CH.sub.2).sub.p --X wherein p represents an integer of 1 to 6, and X represents hydroxy, lower alkoxy or --NR.sup.2a R.sup.2b wherein each of R.sup.2a and R.sup.2b independently represents hydrogen, lower alkyl, or --(CH.sub.2).sub.m --Y wherein m represents an integer of 1 to 6, and Y represents hydroxy, lower alkoxy or --NR.sup.3a R.sup.3b wherein each of R.sup.3a and R.sup.3b independently represents hydrogen or lower alkyl

Pyrazoloacridone derivatives

Disclosed are mitomycin derivatives of formula (I): ##STR1## where W represents halogen; X represents methoxy, amino or ethylenimino; Y represents hydrogen or methyl; Z represents hydrogen or methyl; and one of R.sup.1 and R.sup.2 represents carbamoyloxymethyl, and the other represents hydrogen. The derivatives are usable as an antitumor and antibacterial agent.

Halogen substituted mitomycin derivatives

Disclosed in a mitomycin derivative represented by the formula (I): ##STR1## wherein W is a heterocyclic group.

Growing community of inventors

Fujisawa, Japan

Masaji Kasai